Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center observational study follows 60 adults starting anti-VEGF therapy in one eye to see if repeated injections with eyelid speculum use are linked to blepharoptosis. Participants are assessed at baseline, 1, 3, and 6 months for eyelid height and function using MRD-1, MRD-2, and levator measurements, with the fellow eye serving as control. No intervention beyond standard care is performed; the injection choice, interval, and number are decided by the treating clinician. The study cannot separate the mechanical effect of the eyelid speculum from the injection itself, but it aims to determine if eyelid changes differ between injected and non-injected eyes over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Planned initiation of intravitreal anti-VEGF injection in one eye only for a retinal disease
* No prior intravitreal injection in either eye
* Able to attend the scheduled follow-up visits and to cooperate for the duration of the study
* Reliable MRD-1, MRD-2 and levator function measurement possible in both eyes (clear corneal light reflex, clearly visible eyelid margin, able to maintain primary gaze)
* Signed informed consent

Exclusion Criteria:

* Pre-existing blepharoptosis or significant eyelid malposition at the baseline examination
* Previous ptosis surgery, blepharoplasty or other eyelid surgery that may affect upper eyelid anatomy
* History of myasthenia gravis, oculomotor nerve palsy, Horner syndrome, facial nerve palsy or a similar neurologic or neuromuscular disorder
* History of orbital trauma, orbital surgery or orbital disease
* Advanced dermatochalasis, eyelid retraction, entropion, ectropion or marked facial asymmetry precluding reliable eyelid measurement
* Need for intravitreal injection in both eyes during the study period
* Ocular or periocular surgery during follow-up that may affect upper eyelid position
* Inability to comply with follow-up visits or incomplete measurements
* Withdrawal of consent
* Inability to obtain reliable eyelid measurements due to severe blepharospasm, advanced corneal opacity, marked eyelid edema, or inability to maintain head or neck position or to cooperate

Where it's running

• University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Abdulkadir Küçük, MD
• Email: akkucuk42@gmail.com
• Phone: +90 538 572 5722

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Switching from ranibizumab to aflibercept for eye conditions

  This study is testing if switching patients with certain eye conditions from one medication to another can help improve their vision.

  Recruiting Medical University of Vienna · Vienna · NCT02669953

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.